Targeting specificity is crucial for the success of miRNA therapy. Nanocarriers can be functionalized with ligands, antibodies, or aptamers that recognize and bind to specific cell surface markers. This ensures that the miRNA payload is delivered precisely to the diseased cells, minimizing off-target effects and improving therapeutic outcomes.
